CDEK
← All drugs Report issue

live attenuated influenza virus vaccine

Trade name: Flumist

Vaccineapproved

Approved

Jun 17, 2003

Live attenuated influenza vaccine (LAIV) is a type of influenza vaccine in the form of a nasal spray that is recommended for the prevention of influenza. — Wikipedia

Clinical trial activity

127 trials · 130 clinical orgs · 2 marketing orgs

Phase 1
24
Phase 2
47
Phase 3
29
Phase 4
52

Earliest trial started Oct 1, 1998 (NCT00138294)

Timeline

1990s

  1. Jan 1, 1999

    MedImmune — Earliest Phase 3 Sponsor(trial)

2000s

  1. Jan 1, 2000

    MedImmune — Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2002

    MedImmune — Earliest Phase 1 Sponsor(trial)

  3. Jun 17, 2003

    MedImmune — Earliest FDA Approval

  4. Jun 17, 2003

    MedImmune — NDA Organization

  5. Jun 17, 2003

    AstraZeneca — NDA Secondary Org

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedJun 17, 2003

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • a/california/07/09 live monovalent h1n1 vaccine
  • caivt
  • caiv-t
  • cold-adapted influenza vaccine trivalent
  • flumist
  • flumist
  • flumist/b/victoria
  • flumist/b/yamagata
  • flumist quadrivalent
  • flumist quadrivalent
  • influenza vaccine live, intranasal
  • live attenuated h1n1 influenza vaccine
  • live attenuated h2n3 influenza virus vaccine
  • live attenuated h7n9 anhui 2013/aa ca
  • live attenuated influenza vaccine
  • live, attenuated influenza vaccine
  • live attenuated influenza virus
  • live attenuated monovalent a/17/mallard/netherlands/00/95(h7n3) influenza vaccine
  • live, trivalent influenza vaccine
  • medi3250
  • medi3414
  • medi8662
  • quadrivalent live attenuated influenza vaccine
  • quadrivalent live attenuated influenza vaccine, q/laiv
  • trivalent flumist

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06841913Phase 4Oct 1, 2026National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), University of North Carolina at Chapel Hill
NCT07093281Phase 4Nov 30, 2025University of Maryland
NCT07232745Phase 4Oct 12, 2025Government of China
NCT07240922Phase 4Oct 1, 2025The University of Hong Kong
NCT07177417Phase 4Sep 9, 2025AstraZeneca, Washington University in St. Louis
NCT06740019Phase 1Dec 28, 2024Chinese Academy of Medical Sciences, Jemincare
NCT06501963Phase 4Oct 14, 2024Boston University, Emory University
NCT06609811Phase 4Sep 21, 2024Government of China
NCT05921448Early Phase 1 (Phase 1)Jan 1, 2024Chronic Obstructive Pulmonary Disease Trial Network, Denmark, Novo Nordisk
NCT06280144Phase 4Sep 22, 2023Changchun BCHT Biotechnology Co.
NCT06046092Phase 1Jul 15, 2023University of Oslo
NCT05923515Phase 1May 22, 2023Government of China, Jemincare
NCT05284851Phase 2Apr 1, 2022Changchun BCHT Biotechnology Co., Government of China
NCT04901455Early Phase 1 (Phase 1)Dec 31, 2021National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina at Chapel Hill
NCT05290792N/ADec 10, 2021Canadian Institutes of Health Research (CIHR), McGill University, University of Montreal
NCT05056519Phase 1Sep 20, 2021Changchun BCHT Biotechnology Co., Government of China
NCT04164212Phase 4Jan 31, 2020University of Alabama, Birmingham
NCT04080245Phase 1/Phase 2 (Phase 2)Oct 1, 2019University of Alabama, Birmingham
NCT03982069Phase 4Aug 1, 2019Centers for Disease Control and Prevention (CDC), University of Pittsburgh
NCT03898986Phase 4Jun 30, 2019National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Stanford University
Showing 20 of 127 trials
Page 1 / 7

Organizations

Research & Development (130)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MedImmuneFor profit454251999
National Institute of Allergy and Infectious Diseases (NIAID)Government281241998
WyethFor profit20032000
Stanford UniversityAcademic/Hospital151512008
National Institutes of Health (NIH)Government7032004
University of RochesterAcademic/Hospital7422009
Government of ChinaGovernment6242016
Centers for Disease Control and Prevention (CDC)Government5022013
AstraZenecaFor profit4222014
Changchun BCHT Biotechnology Co.For profit4442016
PATHAcademic/Hospital4432012
Public Health EnglandGovernment4012014
University of LondonAcademic/Hospital4422014
University of North Carolina at Chapel HillAcademic/Hospital4432008
Sponsor GmbHAcademic/Hospital3022004
Canadian Institutes of Health Research (CIHR)Academic/Hospital2022012
Department of Health and Human ServicesGovernment2012009
Duke UniversityAcademic/Hospital2012016
Imperial College LondonAcademic/Hospital2122018
International Center for Diarrheal Disease ResearchAcademic/Hospital2022012
130 organizations
Page 1 / 7

Marketing (2)

OrganizationOrg typeRelationshipDate
AstraZenecaFor profitNDA2Jun 17, 2003
MedImmuneFor profitNDAJun 17, 2003